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Abstract
Multiple myeloma (MM) is a B lymphocyte malignancy that remains incurable despite extensive 
research efforts. This is due, in part, to frequent disease recurrences associated with the persistence 
of myeloma cancer stem cells (mCSCs). Bone marrow mesenchymal stromal cells (BMSCs) play 
critical roles in supporting mCSCs through genetic or biochemical alterations. Previously, we 
identified mechanical distinctions between BMSCs isolated from MM patients (mBMSCs) and 
those present in the BM of healthy individuals (nBMSCs). These properties of mBMSC 
contributed to their ability to preferentially support mCSCs. To further illustrate mechanisms 
underlying the differences between mBMSCs and nBMSCs, here we report that (i) mBMSCs 
express an abnormal, constitutively high level of phosphorylated Myosin II, which leads to stiffer 
membrane mechanics, (ii) mBMSCs are more sensitive to SDF-1α-induced activation of MYL2 
through the G(i./o)-PI3K-RhoA-ROCK-Myosin II signaling pathway, affecting Young’s modulus 
in BMSCs and (iii) activated Myosin II confers increased cell contractile potential, leading to 
enhanced collagen matrix remodeling and promoting the cell–cell interaction between mCSCs and 
mBMSCs. Together, our findings suggest that interfering with SDF-1α signaling may serve as a 
new therapeutic approach for eliminating mCSCs by disrupting their interaction with mBMSCs.
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Multiple myeloma (MM) is a malignant disorder of postgerminal center B-cells.1 MM is 
generally characterized by the clonal expansion of neoplastic plasma cells in the bone 
marrow (BM), presence of monoclonal proteins in blood and/or urine and organ dysfunction 
such as kidney failure, bone density loss and subsequent bone fractures, spinal compressions 
with severe pain, etc.1,2 Despite recent advances in cancer treatments, MM remains an 
incurable disease owing to its proclivity for recurrence, which is believed to be caused by 
minimal residual disease or existence of a myeloma cancer stem cell (mCSC) niche in the 
BM.1,3
BM constitutes a suitable niche for mCSCs, favoring their self-renewal, differentiation and 
development of drug resistance through direct and indirect communications with various cell 
types present in the BM microenvironment.4–7 Among them, BM mesenchymal stromal 
cells (BMSCs) have been extensively studied in the context of MM disease progression and 
resistance to chemotherapeutics. Several studies had shown that BMSCs communicate with 
mCSCs through direct cell–cell interactions and paracrine signaling.4,8–13 In addition, as 
with other cancer-associated stromal cells in a number of cancer types, genetic and 
biochemical abnormalities in BMSCs have also been reported.5–7,9,12,14,15 However, 
distinctions between MM BMSCs (mBMSCs) and normal BMSCs (nBMSCs) are not well 
defined with respect to biomechanics. To partially address this question, our previous study 
reported marked differences in cell stiffness observed between mBMSCs and nBMSCs, 
although the underlying mechanism leading to these differences and how they influenced 
mBMSCs to promote mCSC pathophysiologic functions remained largely unknown.15
Stromal cell-derived factor-1 (SDF-1α) or C-X-C motif chemokine 12 (CXCL12) is a well-
studied member of the chemokine family that specifically activates C-X-C motif chemokine 
receptor 4 (CXCR4).16 One of the major functions of SDF-1α is to promote chemotaxis of 
cancer cells.16 Particularly, SDF-1α is known to promote homing of MM cells to the 
BM,17,18 and to facilitate cell–cell interactions between mCSCs and BMSCs, leading to 
enhanced mCSC survival and proliferation.19,20 It is, however, still unknown how SDF-1α 
affects the biophysical properties of BMSCs and regulates their interaction with mCSCs.
Thus, the aims of our study were three-pronged: (i) to investigate if the differences in cell 
stiffness (defined in terms of cells’ Young’s modulus) are constitutive, (ii) how the cell 
stiffness contributes to the cancer microenvironment and (iii) how SDF-1α affects the 
mechanical properties of BMSCs. Herein, we present the first experimental evidence that 
SDF-1α can increase Young’s modulus in BMSCs by activating the G(i./o)-PI3K-RhoA-
ROCK-Myosin II signaling pathway. Moreover, mBMSCs express a constitutively elevated, 
as compared to nBMSCs, level of activated myosin (MYL2). Finally, our data indicate that 
the activated myosin influences the contractile potential of the cells, which regulates cell–
matrix and cell–cell interactions between mCSCs and mBMSCs.
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Material and Methods
Myeloma cell line culture
RPMI 8226 MM cell line was purchased from ATCC, Manassas, VA and U266B-1 cell line 
was a generous gift from Dr. Jessica Ann Shafer, MD (Texas Children’s Cancer Center, 
Houston, TX). U266B-1 cells were authenticated at the UT MD Anderson Cancer Center 
(Houston, TX). The two cell lines were routinely maintained in RPMI-1640 medium (GE 
Healthcare HyClone™, Logan, UT) supplemented with 10% fetal bovine serum (FBS), 2 
mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (Life Technologies, 
Grand Island, NY). Cells were maintained in a 37°C incubator with a humidified atmosphere 
containing 5% CO2 (Thermo Fisher Scientific, Waltham, MA).
Isolation and expansion of BM mesenchymal stem cells
BMSCs from BM samples of 13 patients (myeloma patients, n =7; monoclonal gammopathy 
of undetermined significance, MGUS, patient n =1; aged-matched healthy donors, n =5) 
were isolated and maintained for up to five passages. The age-matched control nBMSCs 
were obtained from individuals without cytopenia (>55 years old) who received a BM 
evaluation for lymphoma staging, and were determined to be negative for lymphoma 
involvement. We specifically selected these controls to be age-matched for the myeloma 
population to control for the possibility of aging-related functional changes in BMSCs. Use 
of these samples was approved by the Institutional Review Board of the Houston Methodist 
Research Institute. BM mononuclear cells from the myeloma or age-matched controls were 
obtained with Ficoll density gradient medium (1.077 g/ml; Sigma, St. Louis, MO). Cells 
were plated in 175-cm2 tissue culture flasks in MesenPro RSTM with 2% growth 
supplement (Invitrogen, Grand Island, NY). After a 72-hr incubation at 37°C in a 5% CO2 
humidified atmosphere, nonadhering cells were removed and the adherent cells were 
cultured in fresh growth medium for up to five passages, or cryopreserved using the growth 
medium supplemented with 40% FBS and 10% DMSO (Sigma). For further expansion, 
BMSCs were detached with a mixture of collagenase/hyaluronidase (STEMCELL 
Technologies, British Columbia, Canada) and trypsin solution diluted to 0.01% (Life 
Technologies), and plated in 175-cm2 tissue culture flasks or 100-mm dishes coated with rat 
tail collagen type I (0.2 μg/ml in PBS) and Matrigel (0.02 mg/ml in PBS) (BD Biosciences, 
Bedford, MA). This condition for tissue culture vessel coating was able to support the 
proliferation of primary BMSCs, while not allowing for their differentiation. The resultant 
BMSCs were characterized and strong expression of CD44, CD90, CD73 and CD105, and 
absence of CD45 and CD138 was confirmed (Supporting Information Fig. 1).
Hoechst staining for side population
A side population (SP) of cancer cells is characterized by their ability to efflux Hoechest 
33342 dye, which can be detected by flow cytometry. Isolation of SP cells has been 
recognized as an approach to isolate cells with stem-cell-like features,21,22 and has been 
successfully used to identify MM stem cells.13,23 To collect MM SP cell, Hoechst staining 
was performed as described previously.13 In brief, RPMI 8226 cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies) supplemented with 10 
mM HEPES (Invitrogen), 2% FBS and Hoechst 33342 dye (10 μg/ml final concentration). 
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After incubation at 37°C for 60 min, cells were centrifuged and resuspended in cold Hanks’ 
balanced salt solution (HBSS) buffer containing 2 μg/ml propidium iodide (PI) used to 
exclude dead cells. The cell sample was kept on ice cell sorting. Control experiments were 
performed simultaneously by co-incubating the cells with 50 μM verapamil to block 
Hoechst efflux. During cell sorting, the Hoechst dye was excited with a UV laser at 350 nm 
and the light emission was measured with Hoechst blue and red filters. Sorted SP cells were 
collected and used for further experiments.
Micropipette aspiration/cell stiffness assay
The cell aspiration assay was conducted as described previously with minor 
modifications.24,25 Briefly, borosilicate capillary pipettes (Kimble Chase, Vineland, NJ) 
were pulled and forged using a Shutter P-97 puller with the following program parameters: 
heat 483, pull 120, velocity 100 and time 250. Then, the pipettes were coated with SufaSil 
(Pierce Bio-technology, Rockford, IL) as suggested by the manufacturer. Pipette 
manipulation is achieved with a homemade micromanipulator clamped on a microscope 
(Axiovert 200M inverted microscope on a 40× Ph1 LD A-plan, Zeiss, Thronwood, NY), 
while the micropipette is connected to a mobile water tank to produce aspirating pressures. 
The phase-contrast images are taken with a Retiga 2000R (Qimaging, Surrey, BC) and with 
external triggering via Labview 2009 (National Instrument, Austin, TX) to obtain frame 
rates of up to ~50 frames per second. Images were subsequently analyzed either manually 
using the NIH ImageJ draw tool (National Institutes of Health, Bethesda, MA) or with a 
custom tracking program in Matlab 2009b (The Mathworks, Natick, MA) to identify the 
edge of the membrane projection and the changes in the membrane deformation in a given 
time period. The pixel values were converted to μm according to the following ratio: 1 pixel 
=5.536 μm for a 40× objective lens. Minimum aspiration pressure was sought by gradually 
lowering the heights of the mobile water tank from the base height (equal to the height of the 
microscope stage) until the first deformation was seen, and then the length of deformation 
was recorded for 3 sec. In order to find the Young’s modulus of individual nBMSCs and 
mBMSCs, we recorded the cell membrane deformation for 100 sec at a constant water tank 
height. All aspiration assays were performed at a constant pipette-specimen angle. For the 
aspiration of attached cells, cells were cultured on a 35-mm glass-bottom dish precoated 
with collagen, and the medium was changed to hypertonic medium (160 mOsm) just before 
the assay was performed. A Rho-associated coiled coil-forming protein serine/threonine 
kinase (ROCK) inhibitor, Y-27632 (Y), was used at 10 nM. For the suspension cells, cells 
were suspended in serum-free DMEM, and 200 μl cell suspension drops were added onto 
cover slips for single-cell measurement. Fresh drop cell solution was used for measurement 
of each cell to avoid discrepancy in measurement of membrane dynamics due to temperature 
fluctuation and evaporation. The final concentration of SDF-1α used for cell stimulation was 
100 ng/ml. The previously reported model system26 was used to calculate Young’s modulus.
The displacement of cells into the micropipette as a function of time, L(t) in Eq. (1) is
(1)
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where Φ is the ratio of the micropipette wall thickness to the pipette radius, a and ΔP are the 
inner radius and the applied aspiration pressure, respectively. The apparent viscosity, μ, is as 
below where elastic constants k1 and k2 can be determined by solving Eq. (2). τ is the 
exponential time constant.
(2)
These elastic constants, then, can be related to standard elasticity coefficients by the 
following equations, Eq. (3): Eo is the instantaneous Young’s modulus and Einf is the 
equilibrium Young’s modulus.
(3)
Collagen gel contraction assay
BMSCs (1–2 × 105 cells/ml) were embedded in a collagen gel (1.5 mg/ml) as described 
previously27,28 and casted in 48-well plates for 30 min in a humidified CO2 incubator. For 
co-culture with MM cells, U266B-1 cells (1 x 104 cells/ml) or SP of RPMI 8226 cells (5 × 
103 cells/ml) were mixed in the BMSC collagen gels before solidification. For the floating 
gel contraction assay, collagen gels were gently detached from the bottom. The plates were 
scanned after 2 days (for attached gels) or 4 hr (for floating gels). Gel contraction images 
were analyzed with NIH ImageJ software by measuring areas of each gel in square pixels 
and by converting the measurements to square centimeters. The area of the inner well was 
0.95 cm2 as indicated by the manufacturer (48-well plate; Corning, Tewksbury, MA). The 
experiments were repeated at least three times independently using triplicates of each 
experimental group. Pertussis toxin (PT, 50 μg/ml), LY294002 (LY, 20 μM), blebbistatin 
(bleb, 20 μM), Y-27632 (Y, 10 nM), U0126 (U, 10 μM) or AMD3100 (AMD, 25 μM) were 
added together with SDF-1α (100 nM) at the start of the floating gel contraction assay. All 
inhibitors were purchased from TOCRIS Bioscience, Bristol, UK except AMD3100 (Sigma-
Aldrich, St. Louis, MO).
mCSC attachment to BMSCs
Adhesion of mCSCs to BMSCs was investigated as described elsewhere with minor 
modifications.29,30 Briefly, either nBMSCs or mBMSCs (10,000 cells) were plated in 24-
well plates and allowed to grow to confluence. RPMI8226 cells expressing the green 
fluorescent protein (GFP) were stained with Hoechst 33342 dye as described above, 300 SP 
cells were sorted into each well and incubated in a 5% CO2 incubator at 37°C for 4 hr before 
the assay. Before physical shaking for 30 min on rotating shakers at 25 rotations per minute, 
the mCSC-BMSCs were treated with SDF-1α with or without inhibitors (AMD, PT, LY, 
bleb, Y or U) for 2 hr with or without co-treatment. Following incubation, cells were 
carefully washed three times with PBS prewarmed to 37°C, and GFP+ SP cells were 
counted under an inverted fluorescent microscope. Numbers of attached SP cells were 
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normalized to those attached to the control. All experiments were repeated three times 
independently with six replicates per group.
Western blotting
BMSCs were cultured to 80% confluence in 100-mm tissue culture dishes before harvesting. 
Before treatment with SDF-1 or SDF-1α/inhibitor combinations, BMSCs were serum-
starved for 24 hr. All inhibitors were added to the cells 30 min before SDF-1α stimulation. 
The cells were lysed and cellular proteins were collected in RIPA buffer (Pierce 
Biotechnology) supplemented with a protease/phosphatase inhibitor cocktail (Pierce 
Biotechnology), and their concentration was quantified by a BCA assay (Pierce 
Biotechnology). Equal amounts of protein (30 μg) were loaded into each well and resolved 
by SDS-PAGE, followed by Western blotting analyses for p-Erk, p-Akt, p-FAK, p-MYLII, 
MYLII, Erk, Akt, CXCR4, CXCR7 and β-actin. All antibodies were purchased from Cell 
Signaling Technology (Boston, MA) unless specified otherwise. Anti-human CXCR4 and 
CXCR7 antibodies were purchased from Abcam (Cambridge, MA). The dilution factor for 
all primary antibodies was between 1:1,000 and 1:500, while the secondary antibodies (GE 
Healthcare, Piscataway, NJ) were diluted to 1:2,000 and 1:3,000. Signal was visualized by 
chemoluminescence (ECL solution, GE Healthcare).
Detection of active RhoA
BMSC protein extracts (1 mg) were subjected to the Rhotekin Rho-binding domain (RBD) 
agarose bead pull-down assay (Cell BioLabs, San Diego, CA) according to the 
manufacturer’s protocol.31 Briefly, cell extracts were reacted with the RBD agarose beads 
for 1 hr at 4°C followed by serial washing with a provided buffer. The collected agarose 
beads were then mixed with 2× reducing SDS-PAGE sample buffer and boiled for 5 min. 
The supernatant was collected and subjected to Western blotting for pRhoA and RhoA. 
Equal protein loading was confirmed by probing the membranes with an anti-actin antibody.
Statistical analysis
A two-tailed Student’s t-test was used for two-sample comparison. For more than two 
samples, one-way ANOVA were used. The significance was given by the p-value, which 
was considered significant when less than 0.05.
Results
mBMSCs exhibit a constitutively high level of tensile stress
To investigate the biomechanical properties of mBMSCs, their cellular membrane dynamics 
were measured by a micropipette aspiration assay (Fig. 1a, left panel), where nBMSCs were 
used as a baseline control. The average minimum aspiration pressure to initiate membrane 
deformation in the attached mBMSCs was 4.3 kPa, while it was 3.1 kPa in the control 
nBMSCs (p < 0.0001, Fig. 1a, right panel). There was no statistical difference in the length 
of membrane deformation (Fig. 1a, middle panel). Interestingly, pretreatment of mBMSCs 
with Y-27632, an inhibitor of ROCK kinase that regulates Myosin II cellular functions, 
significantly lowered the minimum aspiration pressure in mBMSCs from 4 to 1.5 kPa (p < 
0.0001) (Fig. 1b). Subsequently, the Young’s modulus of mBMSCs, as well as control 
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nBMSCs, was kinetically monitored by recording the membrane deformation in a time 
course. As shown in Figure 1c, Young’s modulus of mBMSCs was on average 400 Pa, and 
around 200 Pa in nBMSCs (p < 0.01). As SDF-1α is a critical factor regulating cell–cell 
interactions and can mobilize myeloma cells in vivo, mBMSCs and nBMSCs were treated 
with SDF-1α and the changes in the Young’s modulus were measured. Treatment with 
SDF-1α increased the Young’s modulus of mBMSCs from 400 to 530 Pa (p < 0.05), and in 
nBMSCs from 200 to 450 Pa (p < 0.05). Taken together, these results imply that mBMSCs 
exhibit a constitutively high level of tensile stress, which can be further enhanced by 
SDF-1α stimulation.
mBMSC tensile stress can be increased by the interaction with cancer cells or SDF-1α 
stimulation
We explored the effects of cell–cell interaction on BMSC biophysical properties using the 
collagen gel contraction assay in the presence or absence of MM cancer cells. We found that 
mBMSCs induced 50% gel contraction, while nBMSCs had no effect on the collagen gels (p 
< 0.0001) (Fig. 2a). Interestingly, addition of U266B-1 MM cells enhanced the mBMSC gel 
contracting ability by ~40% (p < 0.05), but showed little effect on nBMSCs under similar 
conditions (Fig. 2b). Because CSCs are known to reside within a specialized BM niche and 
to be largely resistant to chemotherapeutic agents, we then investigated whether their direct 
interaction with BMSCs affected the biophysical properties of the stromal cells. To 
investigate if SP cells (or mCSCs) could induce gel contraction through BMSCs, SP cells 
were isolated from cultured RPMI 8226 MM cells. Co-culture between mBMSCs and SP 
cells induced about 50% contraction of the collagen gels, but showed no effect when added 
to nBMSCs (Fig. 2c). Notably, despite CXCR4 or CXCR7 expression (Supporting 
Information Fig. 2), MM cells alone or SP cells alone did not induce contraction of the 
collagen gels (data not shown). These findings demonstrate that there is a specific functional 
interaction between mBMSCs and MM cancer cells.
We recently reported in silico modeling prediction that the paracrine SDF-1α/CXCR4 loop 
between mBMSCs and mCSCs may be critical mCSC self-renewal.20 Therefore, we 
expanded our studies to the floating collagen gel contraction assays, where SDF-1α 
signaling was regulated by a number of kinase inhibitors. As shown in Figure 2d, untreated 
(control) mBMSCs resulted in significant gel contraction (~60%), which was further 
enhanced by 20% following SDF-1α treatment (p < 0.05). Interestingly, the SDF-1α-
enhanced gel contraction was inhibited by AMD3100 (AMD, a competitive antagonist of 
SDF-1α), pertussis toxin (PT, a G-protein-coupled receptor inhibitor, G(i./o)-subunit 
specific) or LY294002 (LY, a PI3K inhibitor). Conversely, the SDF-1α-induced gel 
contraction was not inhibited by U0126 (U, MEK inhibitor). Finally, a profound gel 
contraction inhibition was observed by treating the cells with ROCK inhibitor (Y) or Myosin 
II inhibitor blebbistatin (Bleb), irrespective of SDF-1α treatment. These results indicate that 
abnormal tensile stress produced by mBMSCs on collagen gels results from the constitutive 
activation of the RhoA-ROCK-Myosin II pathway, which can be further enhanced by 
SDF-1α stimulation that follows the G(i./o)-PI3K to ROCK-Myosin II signaling cascade (see 
model in Fig. 6).
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SDF-1α promotes the cell–cell interaction between mCSCs and mBMSCs
Several studies had shown that mCSCs are resistant to chemotherapy and radiotherapy in 
part because of their direct cell–cell interactions with BMSCs.4,6,15,19,32 Thus, we then 
evaluated whether SDF-1α promotes cell–cell interactions between mCSCs and BMSCs. As 
shown in Figure 3a, compared to the nBMSC control, there was an increase of 50% when 
mCSCs were plated with mBMSCs under the same experimental conditions (p < 0.05). This 
interaction between mCSCs and mBMSCs was completely inhibited by treatment of cells 
with AMD, PT, LY, Y or Bleb inhibitors (Fig. 3a). Conversely, treatment of cells with 
AMD or PT had no significant effects on mCSC/nBMSC interactions, unlike treatment with 
LY, Y and Bleb inhibitors, suggesting a potential SDF-1α-independent mechanism of cell–
cell interaction between mCSCs and nBMSCs.
To further investigate the effects of SDF-1α on mCSC/mBMSC cell–cell interactions, cell 
attachment assays were performed in the presence of SDF-1α with or without co-treatment 
with the inhibitors. First, SDF-1α treatment enhanced the attachment of mCSCs to 
mBMSCs by more than twofold (p < 0.001) when compared to the baseline control (Fig. 
3b). This enhanced cell binding was completely blocked by pretreatment with AMD, PT, 
LY, Y and Bleb inhibitors (p < 0.001). Unexpectedly, in contrast to our observations in the 
gel contraction assays, the SDF-1α-induced cell–cell interactions were also inhibited by 
MEK inhibitor, U0126. These results imply that the SDF-1α-stimulated cell–cell 
interactions could be regulated through the activation of CXCR4 G(i./o), with the 
downstream signaling transduction pathways bifurcating to PI3K and MEK (proposed 
signaling model, Fig. 6).
SDF-1α activates RhoA through PI3K and MAPK pathways
To dissect signaling events activated by SDF-1α, phosphorylation of myosin light chain II 
(MYL2, a classical regulatory subunit of myosin II), Akt, Erk and FAK was examined in 
nBMSCs and mBMSCs. Presence of SDF-1α at as low as 10 ng/ml induced phosphorylation 
of Erk in both nBMSCs and mBMSCs, while Akt phosphorylation was observed only in 
mBMSCs when stimulated with 50 ng/ml of SDF-1α (Fig. 4a). Notably, the enhanced 
phosphorylation of Akt in mBMSCs was not caused by increased levels of either CXCR4 or 
CXCR7 (Fig. 4a and Supporting Information Fig. 3). Phosphorylation of FAK in nBMSC 
reached its maximum at 5 min and returned to the basal level at 10 min following SDF-1α 
stimulation. In contrast, FAK phosphorylation in mBMSCs was higher at 5 min, and its level 
was maintained for up to 10 min (Fig. 4b). Importantly, treatment with SDF-1α induced a 
rapid phosphorylation of MYL2 that lasted over 10 min in mBMSCs, but had only a 
minimal effect in nBMSCs (Fig. 4b). Moreover, assays using the rhotekin Rho-binding 
domain (RBD) agarose beads31 revealed that phosphorylation of RhoA, an upstream 
regulator of MYL2, was triggered by SDF-1α treatment in mBMSCs and lasted for over 10 
min (Fig. 4c), while it was minimal in nBMSCs. Additionally, phosphorylation of MYL2 
induced by SDF-1α was sensitive to LY, U, PT and AMD, suggesting that the activation of 
RhoA by SDF-1α depends on the G(i./o) subunit, PI3K and MEK. We then investigated 
further components of the SDF-1α–MYL2 signaling pathway in mBMSCs by comparing 
Akt and Erk phosphorylation levels subsequent to treatment with inhibitors indicated in 
Figure 4d. As expected, SDF-1α treatment induced phosphorylation of Akt, Erk and MYL2 
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over the baseline, while inhibition of PI3K (by LY) or MEK (by U) signaling caused a 
reduction in MYL2 phosphorylation to a level lower than the baseline. Moreover, treatment 
of cells with AMD or PT inhibited the SDF-1α-stimulated phosphorylation of Akt and 
MYL2, but had no effect on the phosphorylation of Erk. Our data further indicate that this 
sustained Erk phosphorylation was due to the simultaneous stimulation of CXCR7 
(Supporting Information Fig. 4). Finally, Bleb directly inhibited the SDF-1α-mediated 
phosphorylation of MYL2, without affecting phosphorylation of the upstream regulators. 
Conversely, inhibition of ROCK (by Y) strongly reduced MYL2 phosphorylation, similar to 
that observed with LY or U. Together, these data indicate that the activation of RhoA-
ROCK-MYL2 by SDF-1α mainly depends on the activation of the CXCR4/G(i./o)-PI3K 
signaling pathway or the CXCR4-MEK pathway.
Constitutive activation of Myosin II in mBMSCs
On the basis of the biochemical and physical differences in nBMSCs and mBMSCs, we 
compared signaling biomarkers governing their biophysical properties. For these studies, we 
used BMSCs collected from five nonmyeloma patients, one MGUS patient and seven 
myeloma patients (Fig. 5). First, we found that the expression of CXCR4, Akt, Erk1/2 and 
MYL2 varied among the normal and myeloma BMSCs, but there were no significant 
differences detected between the groups. However, phosphorylation of FAK, Akt and 
MYL2 was upregulated in mBMSCs when compared to the nBMSC samples. Specifically, 
phosphorylation of MYL2 (pMYL2) was markedly higher in mBMSCs than in the 
nonmyeloma-associated BMSCs. Additionally, gene expression analysis of microarray 
analysis (Supporting Information Fig. 5) highlighted upregulated gene expression involved 
in the G-protein signaling (negative regulator of GPCR signaling, RGS4, 2.97 fold change), 
the PI3K/AKT pathway (p ≤6.77E−3) and the RHO family proteins (RHOJ, 3.05 fold 
change) in mBMSCs. These results confirm that mBMSCs are characterized by a 
constitutively activated Myosin II, which may foster an abnormally high mBMSC tensile 
stress observed in the BM of MM patients. We summarized the potential signaling pathways 
involved in these mBMSC biophysical alterations in Figure 6, as we believe that the SDF-1α 
signaling in these cells occurs via a simultaneous activation of PI3K and MEK signaling 
cascades, which lead to activation of MYL2 and regulation of cell stiffness, ECM 
modification and mCSC adhesion to mBMSCs.
Discussion
In our study, we demonstrated that stiffer cell membrane mechanics in mBMSCs were 
associated with higher tensional stress, which was regulated by the RhoA-ROCK-MYL2 
signaling pathway (Fig. 6). We also showed for the first time that compared to nBMSCs, 
mBMSCs exhibit a higher level of phosphorylated MYL2 and FAK, indicating a constitutive 
tensional stress in mBMSCs. We also demonstrated that mBMSCs were significantly more 
effective in inducing collagen I gel contraction, while nBMSCs did not induce contraction of 
gels under similar conditions. Previous reports showed that tissue stiffening is associated 
with cancer-induced activation of integrins and focal adhesions in cancer-associated stromal 
cells, resulting in increased tensional stress in the cancer microenvironment.33,34 Moreover, 
this increase in the tensional stress is associated with enhanced angiogenesis, cancer cell 
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proliferation and metastasis.33–35 Thus, our results suggest that matrix stiffening can occur 
in BM of MM patients, which, in turn, could promote disease pathogenesis.
In the next set of experiments, we correlated the significance of stiffer mBMSC 
biomechanics with stronger mCSC to mBMSC cell–cell binding compared to nBMSCs. Our 
results fit well in the breadth of experimental data showing that MM cells acquire various 
advantages, such as maintenance of CSCs, acquisition of drug resistance and differentiation, 
by physically coupling with BMSCs.4,5,12,13,19,36 Treatment with SDF-1α increased the 
stiffness of both nBMSCs and mBMSCs as did cell–cell interactions and the collagen I gel 
contraction. SDF-1α was originally identified as a stromal cell-secreted growth factor and as 
a chemoattractant for MM CSCs homing to the BM.37 Moreover, SDF-1α is known to 
promote a physical cell–cell contact between BMSCs and mCSCs, leading to a hypothesis 
that SDF-1α antagonist, AMD3100, could be used as an adjuvant MM therapy to decrease 
survival of MM stem cells.19
In light of its obvious importance in the progression of MM, it is also important to consider 
biological sources of SDF-1α within the tumor microenvironment. Others previously 
reported that mBMSCs produce significantly lower levels of SDF-1α than do nBMSCs as 
MM disease progresses.12 In contrast, another study clearly illustrated that SDF-1 was 
produced by the MM cells themselves.38 In our setting, we found that SDF-1α secretion was 
higher in CSCs than in non-CSCs (data not shown). Others had shown that cancer cells 
modify their microenvironment through continuous active and passive interactions with their 
host cells.9,12,34,39–41 Hence, cancer-associated stromal cells, including BMSCs, are known 
to undergo genetic, biochemical and physical alterations as tumors progress. On the basis of 
our results, we then propose that mCSC-borne SDF-1α may promote BMSCs to acquire 
stiffer biomechanics.
CXCR4, a G-protein-coupled receptor (GPCR), consists of three G-protein subunits, Gα, Gβ 
and Gγ.42,43 Among the three subunits, the Gα subunit is the major constituent of GPCRs, 
propagating diverse downstream signaling pathways upon its activation. Consequently, the 
same ligand–receptor interaction can conceivably result in different cellular activities.42 Our 
data suggest that SDF-1α activates the G(i./o)-RhoA-ROCK-Myosin II signaling pathway in 
BMSCs, leading to increase in cell stiffness. Also, activation of G(i./o) in the CXCR4 
signaling cascade can be propagated through either PI3K alone or through both MEK and 
PI3K pathways simultaneously following the interaction of mBMSCs with collagen gels or 
mCSCs, respectively. Interestingly, we noted that compared to nBMSCs, mBMSCs were 
more sensitive to SDF-1α-induced activation of Akt and FAK that are downstream targets of 
PI3K. At the same time, we did not observe qualitative differences in the expression of 
CXCR4 between nBMSCs and mBMSCs. Therefore, data imply that presence of MM cells 
in the BM causes loss of negative regulators of the SDF-1α-CXCR4 signaling pathway. 
Supporting this notion, regulators of G-protein signaling (RGS), as well as growth factor 
independent-1 (GFI1), were identified as negative regulators of CXCR4 in multiple cell 
types.44–48 Finally, CXCR7 can desensitize the CXCR4 signaling pathway, especially with 
regard to the Gαi protein-dependent signaling.49
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In conclusion, we identified that higher activation of the RhoA-MYL2 pathway confers 
stiffer cell membranes and higher contractility in mBMSCs, resulting in stronger cell–cell 
interactions between the BM stromal cells and mCSCs and in remodeling of the BM 
extracellular matrix. Also, we demonstrated that mBMCSs are more sensitive to SDF-1α-
CXCR4 activation, which enhances the biomechanical characteristics of mBMSCs, thus 
supporting mCSCs. Our data lend support for further detailed studies aimed to characterize 
how the physical components of BMSCs support mCSCs, and to potentially identify novel 
therapeutic targets. Finally, our data suggest that caution should be exercised when MM 
patients received autologous BM transplants following lethal chemotherapy or radiotherapy 
because this transplanted BM may contain not only the minimal residual disease but also the 
mCSC-supporting BM stromal cells.
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What’s new?
Multiple myeloma remains an uncurable disease in part because of the persistence of 
myeloma cancer stem cells that remain in specific niches in the bone marrow. Here, the 
authors established a novel function of stromal cell-derived factor (SDF)–1α in altering 
biomechanics of myeloma-associated bone marrow mesenchymal stromal cells through 
the activation of myosin II. They further determined that the altered biophysical 
characteristics play a critical role in regulating the interactions between the stroma and 
myeloma cancer stem cells. Collectively, the results suggest that matrix stiffening can 
occur in the bone marrow of multiple myeloma patients which in turn can promote 
disease pathogenesis.
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Figure 1. 
mBMSCs have stiffer membrane mechanics than nBMSCs. (a) mBMSCs require a higher 
minimum aspiration pressure to initiate membrane deformation compared to nBMSCs. (b) 
Inhibition of ROCK lowered the aspiration pressure for deformation initiation in mBMSCs. 
(c) Measurements of Young’s modulus of nBMSCs and mBMSCs in the absence or 
presence of SDF-1α.
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Figure 2. 
Remodeling of extracellular matrix by mBMSCs. (a) mBMSCs display a higher tensile 
stress on collagen gels. (b and c) Addition of myeloma cells or myeloma-derived SP cells 
enhances the contractile potential of mBMSCs. (d) SDF-1α enhances gel contraction by 
mBMSCs, which is inhibited by AMD, PT, LY, Y or Bleb inhibitors.
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Figure 3. 
Preferential attachment of mCSCs to mBMSCs depends on SDF-1α. (a) mBMSCs promote 
mCSC adhesion, which is sensitive to inhibition of the SDF-1α signaling pathway. (b) 
SDF-1α induced mCSC attachment to mBMSCs and can be inhibited by the addition of 
AMD, PT, LY, Y, U and Bleb inhibitors.
Choi et al. Page 18
Int J Cancer. Author manuscript; available in PMC 2015 June 03.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 4. 
SDF-1 signaling pathways in mBMSCs. (a and b) Treatment of mBMSCs with SDF-1α 
results in higher levels of MYL2, Akt and FAK phosphorylation when compared to 
nBMSCs. (c) SDF-1α stimulates phosphorylation of RhoA, an upstream regulator of MYL2, 
in mBMSCs, but not in nBMSCs. (d) Phosphorylation of MYL2 by SDF-1α depends on 
activation of G(i./o), PI3K, MEK and ROCK.
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Figure 5. 
Phosphorylation of FAK, Akt and MYLII is constitutively elevated in mBMSCs. 
Phosphorylation of FAK, Akt and MYLII is constitutively elevated in mBMSCs (M1 to M7) 
compared to nBMSCs (N1 to N5). MF and MGUS refer to myeloid fibrosis and monoclonal 
gammopathy of undetermined significance, respectively.
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Figure 6. 
A proposed model of biophysical regulation of mBMSCs. Binding of SDF-1α ligand to its 
cognate receptors CXCR4 or CXCR7 results in the activation of PI3K or MEK. 
Subsequently, MYL2 is phosphorylated, which leads to changes in cell stiffness, ECM 
modification and adhesion of mCSCs to mBMSCs. Pathway 1 indicates the CXCR4-Gα(i/o)-
PI3K-RhoA-ROCK-MYL2 pathway, while pathway 2 indicates the CXCR4-MEK-RhoA-
ROCK-MYL2 pathway. Question marks indicate possible, but unconfirmed, pathways. 
Arrows indicate activation of downstream molecules. MLCK refers to myosin light chain 
kinase.
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